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Recombinant Human Bone Morphogenetic Protein-2
and Collagen for Bone Regeneration
Jeffrey O. Hollinger,1 John M. Schmitt,1 David C. Buck,1 Robert Shannon,1 Seong-Pil Joh,1
H. Daniel Zegzula,1 John Wozney2
1 Oregon Health Sciences University, Division of Plastic and Reconstructive Surgery, Portland, Oregon 97201-3098
2 Genetics Institute, Andover, Massachusetts
Abstract: The study reported describes a combination of recombinant human bone 
morphogenetic protein-2 (rhBMP-2) and collagen (C) to regenerate bone. Unilateral 
critical-sized defects (CSDs) were prepared in radii of 32 skeletally mature New Zealand 
white rabbits. Rabbits were divided evenly among four treatments: autograft, absorbable 
C (Helistatt) ,  35  mg of rhBMP-2 combined with absorbable C (rhBMP-2/C),  and  un-
treated CSDs. The two euthanasia periods were 4 and 8 weeks. Radiographs were taken 
the day of surgery, every 2 weeks, and at term and the percent of radiopacity was 
measured. Data analysis revealed a time-dependent increase in the percent radiopacity 
with rhBMP-2/C. Histological examination revealed the rhBMP-2/C treatment regener-
ated osseous contour by 8 weeks. According to quantitative histomorphometry, the CSD 
and C groups had significantly less new bone than either autograft or rhBMP-2/C (p °
0.05). The results suggest that rhBMP-2/C could be an effective therapy to restore seg-
mental bone defects. 
Keywords: bone morphogenetic protein; bone regeneration
INTRODUCTION important roles, such as allowing the surgical placement
of the therapeutic agent, preventing soft tissue prolapse,
and localizing rhBMP-2 at the wound site for interactionThe capacity for bone to regenerate is well known. How-
with cells. Several categories of materials were selected as
ever, the ability to restore form and function without scar delivery systems for BMPs, including calcium-phosphates,formation is size limited and the concept of the critical- biodegradable polymers, bone derivatives, and C.15 Selec-
sized defect (CSD) reflects this physiologic phenomenon.1
tion criteria for delivery systems were based on expediencyAugmentation of bone deficits with various therapies has
and physiological merit: expediency because some materi-become a common practice, and autogenous grafts and
als were available as clinical therapies acceptable to the
allogeneic bone bank preparations provide effective thera- Food and Drug Administration (FDA) and physiologicalpies. Yet, despite the effectiveness of these traditional ther-
merit because some materials fulfill biological, functional
apies, recognized liabilities2,3 have prompted a quest for
roles. We selected a C vehicle for rhBMP-2 based on the
alternatives.4 A potential alternative has been developed
notion that a commercially available, FDA-approved Cthat consists of recombinant human bone morphogenetic
therapy for hemostasis could deliver rhBMP-2 and promoteprotein-2 (rhBMP-2) and collagen (C). bone regeneration. This notion is not unfounded becauseThe efficacy and safety of rhBMPs were well docu- demineralized bone matrix, principally type I collagen and
mented in numerous preclinical trials in several animal
soluble signaling factors ( including BMPs), has a proven
models5–13 and in a recent provocative clinical report. 14 A
record for bone repair. 16
reoccurring theme in these studies was the emphasis on In light of the bone inductive potency of rhBMP-2 andthe delivery system for rhBMP. The delivery system fulfills
the conviction that a commercially available C therapeutic
would fulfill an effective role as a delivery system, we
proposed the hypothesis that the combination of a selected
dose of rhBMP-2 plus Helistatt C (rhBMP-2/C) would
Correspondence to: Dr. J. O. Hollinger (e-mail: hollinge@ohsu.edu) promote an amount of bone equivalent to a traditionalContract grant sponsor: NIH; contract grant numbers: DE11416 and HD12113
Contract grant sponsor: Genetics Institute ‘‘gold standard’’ ( i.e., autograft) . Therefore, to test this
hypothesis we designed a study using a CSD segmental
Surgical Procedures and Treatment
Surgery. The New Zealand white rabbits were anesthe-
tized with 10 mL of ketamine hydrochloride, 100 mg/mL
Ketaset (Fort Dodge Laboratories, Inc., Fort Dodge, IA),
5 mL of xylazine, and 20 mg/mL Gemini SA (Burns Veter-
inary Supply, Inc., Rockville Center, NY) at a dose of 0.65
mL/kg body weight administered intramuscularly (i.m.) .
Enrofloxacin (25 mg/kg, Baytril, Miles Inc., Shawnee Mis-
sion, KS) was given i.m. The operative site on either the
left or right front limb was shaved, prepped, and draped
for aseptic surgery with the rabbit in the supine position.
A tourniquet was placed around the axillary region and the
operative site was infiltrated with 0.5 mL of 2% lidocaine
with epinephrine 1:100,000, 20 mg/mL xylocaine (Astra
Pharmaceutical Products Inc., Westborough, MA). A 4-
cm length superomedial incision was made and the tissues
were dissected overlying the diaphysis of the radius. A 20-
mm segmental defect was made in the radius with a surgical
oscillating saw supplemented by copious 0.9% sterile sa-
line irrigation, and the appropriately designated treatmentFigure 1. A scanning electron microscope micrograph reveals the
highly fibrous and porous structure of the collagen delivery system. was placed in the CSD. Fixation of the ostectomized bone
was unnecessary due to the fibro-osseous union between
the ulna and radius located distal and proximal to the surgi-
cal site. The soft tissues were approximated with inter-
rupted 4-0 Vicryl sutures (Ethicon Inc., Somerville, NJ)wound model and four treatment groups: autograft, rhBMP-
2/C, C, or untreated CSD. and the skin was closed with surgical staples (Precise DS-
25, 3M, St. Paul, MN). Immediately after surgery, stan-Our goal is to develop a therapy that may be an alterna-
tive to either autografts or allogeneic preparations. Based dardized lateral radiographs were taken of the operated
limb after which the animals were returned to their individ-on the evidence from this study, it appears rhBMP-2/C
may be an effective therapy to restore segmental osseous ual cages. Postoperative analgesia (Buprenex, 0.3 mg/mL,
0.3 mL i.m., Reckitt and Coleman Pharmaceuticals Inc.,defects.
Richmond, VA) was given as needed. Water and food were
supplied ad libidum.
MATERIALS AND METHODS Treatments. The autograft was prepared as a cortico-
cancellous block from the operated site. For the C and
rhBMP-2/C treatments, 0.17 mL of buffer containing ei-Unilateral, 20-mm length CSD ostectomies were prepared
ther 0 or 35 mg of rhBMP-2 was transferred in a sterilein the radial diaphyses of 32 skeletally mature New Zealand
fashion to the collagen by syringe and placed within therabbits. Skeletal maturity was verified radiographically by
ostectomy gap [Fig. 2(A,B)] . Treatments were retainedclosure of the epiphyseal plates. The 32 rabbits were di-
and stabilized by approximating flexor and extensor ten-vided evenly between two time periods (4 and 8 weeks)
dons and simple soft tissue closure. The fourth group con-and among four treatment groups. Treatments consisted of
sisted of untreated CSDs.autograft, untreated ostectomy, and Helistatt C either alone
There were four rabbits for each experimental cohort ator with 35 mg of rhBMP-2.
each time period. This quantity was determined by powerThe rhBMP-2 was produced by a Chinese hamster ovar-
analysis from previous data,19,20 indicating that the a riskian cell expression system. The protein was purified to
would be 0.05 and the b risk would be 0.10.21ú98%, placed in sterile glass vials containing a sodium
glutamate buffer (5 mM, pH 4.5), and closed with rubber
stoppers. The rhBMP-2 was provided by Genetics Institute Radiography and Radiomorphometry(Andover, MA). Helistatt C (Fig. 1) was prepared in a
proprietary manner by Colla-Tech, Inc. (a subsidiary of Standardized radiographs were taken immediately postop-
eratively, every 2 weeks in life, and at the time of euthana-Integra Life Sciences Corporation, Plainsboro, NJ) from
bovine tendon. Helistatt is a crosslinked atelopeptide prod- sia. Briefly, the surgical sites were radiographed in a stan-
dard manner in a Minishot X-ray cabinet (AXR Corpora-uct that is nonimmunogenic and composed of type I colla-
gen. The ability of Helistatt plus rhBMP-2 to promote tion, East Haven, CT) at 35 kvp, 3 mA, and 25 s using a
constant object to film to X-ray cone distance and ultrahighbone formation was confirmed by previous studies. 17,18
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(Zeiss Instruments Co., Inc., New York). New bone was
detected and measured in square millimeters from the von
Kossa stained specimens using a Leica 970 Image Analysis
System (Leica Instruments Ltd., Cambridge, U.K.) inter-
faced with a Zeiss Axiophot microscope as previously de-
scribed.20,22
Statistical Analyses
Histomorphometry and radiomorphometry data were ana-
lyzed by multiple ANOVA to determine if there was an
overall difference in the percent of radiopacity and area of
new bone among treatments over time. Individual differ-
ences between treatments at each time period were deter-
mined by Fisher’s protected least significant difference test
for multiple comparisons. Statistical significance was es-
tablished at p õ 0.05.
RESULTS
The clinical course for all treatments was uneventful. There
were no indications of adverse sequelae.
Radiography
Throughout the 8-week study, the CSDs did not achieve a
radiopaque union. Autograft-treated recipient sites dis-
played callus formation at 4 and 8 weeks, and consolidation
was more evident at 8 weeks than at 4 weeks. MinimalFigure 2. (A) At the time of surgery, 0.17 mL of buffer containing
radiopacity was observed at the bone margins for the Ceither 0 or 35 mg of rhBMP-2 was transferred in a sterile fashion by
cohort at 4 and 8 weeks; by 8 weeks the recipient sitessyringe to the collagen delivery vehicle. (B) The rhBMP-2/C within
the ostectomy gap. (m ) The edges of the resected radius. treated with rhBMP-2/C had radiopaque bridging (Fig. 3) .
Figure 4 depicts the radiographic progression for the
CSD and 35 mg rhBMP-2/C treatments immediately fol-
lowing surgery and until necropsy. Radiolucency immedi-
contrast mammography film (X-OMATL, Kodak, Eastman ately following surgery (postop day 0) is evident in the
Kodak, Rochester, NY). The X-ray films were assessed by 35-mg rhBMP-2/C group, and from 2 through 4 weeks the
gray level densities and were reported as ‘‘percent radio- radiopacity gradually increased. At 6 weeks a bonelike
pacity’’ across the ostectomy as previously described.20,22 pattern could be noted, and by 8 weeks radiopaque bridging
A standard-sized computer-generated reference frame was with a contour reminiscent of the preostectomized segment
used for each experimental site; if radiopacity completely was apparent. (Verification that radiopacity is new bone
filled the site, a value of 100% radiopacity was recorded. was made by histology.)
Histology and Histomorphometry
Radiomorphometry
Following euthanasia, experimental sites were recovered
as a block and placed immediately into 70% ethanol, taken The 35-mg rhBMP-2/C treatment promoted a significant
increase in the percent of radiopacity from 2 to 4 weeks,to 100% ethanol, embedded in poly(methylmethacrylate) ,
sectioned to a 5-mm thickness, and consecutive serial sec- after which time there was no difference (Fig. 5) . Further-
more, 35-mg rhBMP-2/C treated sites displayed signifi-tions stained either with a modification of the Goldner–
Masson trichrome stain or von Kossa stain. Using bright cantly more radiopacity than either the CSD or C-treated
defects throughout the experiment’s duration. In contrast,field light microscopy, the Goldner–Masson trichrome-
stained sections were examined for cell type, morphology, the autograft recipient beds had a relatively consistent pat-
tern of radiopacity.and stromal detail using a Zeiss Axiophot Microscope
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Figure 3. Representative radiographs of the four treatments at 8 weeks. The radiolucent CSD vali-
dates that the 20-mm ostectomy does not heal by bone formation. A radiolucent junction may be
seen between the autograft and host bone (, ). The 0 mg of rhBMP-2 delivered in C is radiolucent.
The 35 mg of rhBMP-2 and collagen treatment promoted new cortical bone . The host bone is
identified by (m ).
Histology and Histomorphometry partially purified BMP or rhBMP and various delivery sys-
tems used a range of doses, different animal models, andA series of light micrographs for each treatment at 4 and
assorted time periods for assessments. Therefore, it was8 weeks depicts the appearance wound beds (Fig. 6) . At
problematic to extrapolate BMP doses from these studies.4 weeks the recipient beds administered 35 mg rhBMP-
However, some key features from these investigations pro-2/C had numerous bony trabeculae. By 8 weeks the trabec-
vided valuable guidance and should be emphasized to un-ulae were consolidating and cortices were reforming. In
derscore crucial issues of reproducibility and accuracy incontrast, experimental sites treated with either C or left as
animal wound modeling, experimental design, BMP dos-untreated CSDs gradually went on to a fibrotic union. The
ing, and BMP delivery that impact on a therapy for patients.autografts integrated with the host bone through callus for-
Stevenson and colleagues prepared bilateral diaphysealmation.
defects (8 mm in length) in rat femora and reconstructedResidual C was detected microscopically with polarized
them with combinations of hydroxyapatite and tricalciumlight at 4 weeks; none could be detected by 8 weeks (Fig.
phosphate (HA/TCP) amended with 100 mg of partially7). Moreover, there was no evidence of an adverse cellular
purified bovine osteogenin (also known as BMP-3).23 Thisreaction to the C at either 4 or 8 weeks.
dose combined with the HA/TCP cylinder promoted moreHistomorphometric data indicated the CSD and C
bone formation in the HA/TCP devices than HA/TCPgroups had significantly less bone than the other two
without osteogenin. However, Stevenson et al. determinedgroups, whereas no difference was detected between the
there was no biomechanical difference between the two35-mg rhBMP-2/C and autograft groups (Fig. 8) .
treatment cohorts ( i.e., HA/TCP vs. 100 mg BMP-3/HA/
TCP).23 Another long bone study in rat femora involved
unilateral defects that were 4 mm in length.24 The authorsDISCUSSION
reported that at 4 and 8 weeks only the 10 mg of extract
from Saos-2 cells with bovine collagen promoted boneThe results comply with our purpose to regenerate CSDs
union.24in rabbits’ radii with rhBMP-2 and C. Furthermore, we
Yasko et al. used a combination of rhBMP-2 (either 1.4proved the stated hypothesis that a combination of rhBMP-
or 11 mg) and guanidine-hydrochloride extracted deminer-2 and C would regenerate as much bone as the gold stan-
alized rat bone matrix to regenerate ostectomies in rat fem-dard autograft. The autograft formulation has been applied
ora.25 Their evidence suggested that the 11-mg rhBMP-2in previous rabbit studies in our laboratory. Moreover, the
dose caused radiographic bridging of the 5-mm ostectomybone formation response evoked by the segmental autograft
gaps. The authors reported that by week 9 there was acould be measured and compared to the bone formation
cortical bridge across the defect with reconstitution of theresponse promoted by the other experimental treatments.
intramedullary canal.We selected a dose of 35 mg of rhBMP-2 combined with
Marden and coworkers administered either 2.2 or 6.5C for comparison to the autograft. This decision was based
mg of rhBMP-2 with guanidine-hydrochloride extracted de-on previous investigations using the same wound model in
rabbits. 19,20 Reports on long bone regeneration with either mineralized rat bone matrix in craniotomies in rats and
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Figure 4. The radiographic progression CSDs and 35 mg of rhBMP-2 and collagen treatment from
the day of surgery until euthanasia (8 weeks). Both treatments at postop day 0 are radiolucent
immediately after ostectomy. The 35 mg of rhBMP-2 and collagen became slightly radiopaque by 2
weeks. Radiopacity for this treatment increased from 4 through 8 weeks, at which time a dense
radiopaque bridging with a contour reminiscent of the preostectomized segment was apparent.
determined that by 14 days, 6.5 mg of rhBMP-2 completely facial complex versus an extremity. Moreover, recombinant
BMP appears to be 10 000 times more potent than partiallyregenerated the craniotomy.7 In contrast, with a dose of 11
mg rhBMP-2 Yasko and associates observed radiographic purified BMP for regenerating bone in rats. 23,25
A rabbit model used by Bostrom and coworkers consistedbridging by 4.5 weeks and restoration of the cortex and
medullary canal by 9 weeks.25 These two rat studies are of bilateral, 20-mm long ulnar defects and one of several
treatments of polylactic glycolic acid, autogenous blood, andhighlighted to underscore the variability in doses between
two experiments exploiting the same animal and delivery four rhBMP-2 doses (27–300 mg) were administered.11 By
8 weeks the X-ray films showed the two higher rhBMP-2system for rhBMP-2 at different recipient sites. Therefore,
it is noteworthy to review several key observations. In rats, doses promoted union. For histology slides a bone score was
used to compare responses at the wound sites; however, datairrespective of embryogenesis, the intramembranous skull
CSD and the endochondral femur CSD will regenerate in reported were difficult to interpret.11 The authors observed
neither polylactic glycolic acid remnants nor multinucleatedresponse to rhBMP-2. The rate of bone healing appears to
be site specific; for example, the skull CSD regenerated in giant cells at the recipient sites. This observation is contrary
to reports in other studies where a polylactic polyglycolic2 weeks (with 6.5 mg rhBMP-2) whereas the femur (with
11 mg rhBMP-2) required 9 weeks. This observation may acid delivery system either with or without BMP incited a
multinucleated giant cell reaction.9,19,20,26be due to enriched vascularity and cellularity of the cranio-
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Figure 6. Representative micrographs for each treatment at 4 and 8
weeks depict the appearance of healing bone at the wound sites. At
4 weeks the 35 mg of rhBMP-2 and collagen treatment produced
numerous trabeculae and by 8 weeks trabeculae consolidated and
cortices developed. (Bone is stained black) . The CSD and 0 mg of
rhBMP-2 and collagen treatment did not promote new bone forma-
tion. The autograft-treated defects healed by callus formation. von
Kossa stain; original magnification 11.
Figure 5. At week 2, the radiomorphometry data revealed that CSD
the limited and variable number of replicates per treatmentand 0 mg of rhBMP-2 and collagen treatments had equivalent radio-
pacity ( indicated by a) but were different than other treatments. Also cohort and lack of statistics, except for a Student’s t test
at week 2, the radiopacity for the autograft group was greater than to analyze the biomechanical data, which indicated no dif-
the other cohorts ( indicated by b) (p ° 0.05). By 4 and 6 weeks the ferences among treatments.
CSD group had less radiopacity than contemporary treatments (a) ,
Either partially purified BMP or rhBMP-7 has been ap-except for the 0 mg of rhBMP-2 and the collagen group. This relation-
plied to restore long bone segmental defects in dogs.5,28,29ship among groups was consistent for weeks 6 and 8.
Two other important issues concern rhBMP-2 dosing
and wound model selection. We report a 35-mg dose of
rhBMP-2. The elevated rhBMP-2 dose (e.g., 300 mg) se-
lected by the Bostrom group may reflect the need either to
offset liabilities in the delivery system or the instability
caused by a bilateral wound model. We determined in a
pilot study that the unilateral, 20-mm length radius resec-
tion was a stable critical-sized defect and did not compro-
mise function for the experimental animal. We also deter-
mined bilateral 20-mm ostectomies were neither stable nor
permitted the rabbit to favor one limb and resulted in pseu-
doarthrosis in many bilateral wounds treated with 35 mg
rhBMP-2. Therefore, in a critical-sized unilateral rabbit
radius model, 35 mg rhBMP-2 promotes bone regeneration
whereas 300 mg rhBMP-2 promotes bone regeneration in
Figure 7. At 4 weeks the upper panel of a defect implanted with 0bilateral ulnar defects.
mg of rhBMP-2 and collagen (Goldner trichrome stain, original magni-Cook et al. assessed 12 treatment combinations that in-
fication 13.2) . Polarized light reveals residual collagen, which can becluded seven doses of rhBMP-2 combined with guanidine
seen as swirls of polarized fibers ( insert to reader’s right, original
extracted, rabbit derived, demineralized matrix to restore magnification 125). (f ) New bone trabeculae are seen adjacent to
a rabbit ulnar defect model (15 mm in length) . 27 Conclu- the edge of the defect ( insert to reader’s left, original magnification
125).sions about treatment outcomes were ambiguous because of
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cal data did not indicate a significant difference between
the two treatments ( i.e., 500 mg of bovine carrier and 2.5
mg of rhBMP-7 vs. the unoperated limb).
Recombinant human BMP-2 was used to regenerate
CSDs in dogs’ mandibles and osseous continuity of alveo-
lar clefts in dogs.12 Toriumi and colleagues observed that
250 mg of rhBMP-2 plus inactivated, bone derived (dog)
matrix restored mandibular continuity by 6 months33;
Mayer et al. noted 200 mg of rhBMP-2 delivered by
poly(lactide-co-glycolide) regenerated the bony contour of
alveolar clefts in 4 months.12
A study by Cook and colleagues involved 20-mm length
ostectomies in 28 African green monkeys evenly divided
according to wound sites in either diaphyses of tibiae or
ulnae.8 Treatments at the 14 ulnar sites included 1 mg
rhBMP-7 delivered in 400 mg of bovine bone matrix, ma-
trix alone, and autogenous grafts. There were five treat-
ments for the 14 tibiae, including four dose combinations
of rhBMP-7. Results from this study were ambiguous be-
cause of the experimental design with unequal replicates.
Several groups had only one or two animals per treatment.
Moreover, it was unclear what statistical analyses were
used.
A number of reports detailed rhBMPs for long bone
regeneration in sheep,34,35 spine fusion in rabbits and
dogs,9,10,13,36,37 and mandibles in rhesus nonhuman pri-Figure 8. At 4 and 8 weeks the histomorphometry revealed that the
quantity of bone at CSDs and 0 mg of rhBMP-2 and collagen-treated mates.18 Various doses of BMPs and delivery systems (in-
groups did not differ but was significantly less than other treatments cluding polylactic polyglycolic acid, bone derivatives, and
(p ° 0.05). The quantity of bone at defects treated with either 35 mg C) were used. Moreover, in a recent clinical report byof rhBMP-2 and collagen or autograft did not differ ( indicated by a).
Boyne and colleagues, doses of 1.77 to 3.4 mg of rhBMP-
2 were administered to 12 patients in a collagen delivery
system.14 The authors claimed this combination was a use-
ful therapy for augmenting the floor of the maxillary sinus.Nilsson et al. used 100 mg of bovine derived, partially
purified BMP delivered by an aggregate of g-carboxyglu- For our study we chose a commercially available colla-
gen formulation (Helistatt) to deliver rhBMP-2. Thetamic acid, histone 2-B, and calmodulin to restore 25-mm
long ulnae ostectomies in dogs and reported osseous union rhBMP-2 dose was derived from previous laboratory work
indicating three doses of rhBMP-2 (17, 35, and 70 mg)by 12 weeks.28 Heckman and colleagues prepared 3-mm
long ostectomies in the diaphyses of dogs’ radii. 29 Treat- delivered with a porous rod of poly(D,L-lactide) promoted
an equivalent quantity of new bone at 4 and 8 weeks withinments included combinations of polylactic acid, guanidine-
inactivated bovine bone matrix, and partially purified BMP 20-mm length, unilateral CSDs in rabbits’ radii. 19,20 The
area of new bone measured in this study (Fig. 8) wasfrom either bovine or dog sources. The bovine derived
BMP was administered at a dose of 15 mg and the dog consistent with the quantity previously reported.20 The dif-
ference between the two experiments was the carrier forderived partially purified BMP was administered at 1.5 mg
per defect. Results from the Heckman et al. study are diffi- the rhBMP-2: collagen versus poly(D,L-lactide) . It appears
that irrespective of the carrier in a unilateral rabbit radiuscult to interpret for several reasons: the inequity in sample
sizes of two to six among seven treatment groups; ambigu- model, the same dose of rhBMP-2 (i.e., 35 mg) promotes
nearly identical bone healing. The consistency of theseities in statistical analyses; a xenogeneic (bovine) bone
matrix carrier for allogeneic BMP (which is contradictory results helps to fortify the dosing relevancy in bone healing
studies with polymers, such as poly(D,L-lactide) and C.to reports advocating an allogeneic matrix for partially pu-
rified BMP30–32) ; and internal fixation on some dogs and Moreover, the efficacy of Helistatt and rhBMP-2 was re-
ported for maxillofacial reconstruction in monkey mandi-no fixation on others.
Cook et al. reported rhBMP-7 restored 25-mm long, bles and a canine spinal fusion model. 17,18
Helistatt is manufactured as an absorbable collagenunilateral, ulnar ostectomies in six adult mongrel dogs.5
The delivery system was 500 mg of guanidine inactivated sponge for hemostasis control. The Helistatt C is derived
from bovine Achilles tendon treated in a proprietary man-bovine bone matrix. Responses were assessed radiographi-
cally and biomechanically. However, the radiographic ner to render the product nonimmunogenic. Although no
adverse sequelae (clinical or histologic) were observed‘‘grading’’ was not analyzed statistically and biomechani-
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delivery systems for recombinant human bone morphogene-with the Helistatt C used in our model, there are limited
tic protein-2 (rhBMP-2). J. Biomed. Mater. Res. 28:1139–reports of an immune response to bovine C.38,39 The im- 1147; 1994.
mune reaction may be difficult to predict across species and 7. Marden, L. J.; Hollinger, J. O.; Chaudhari, A.; Turek, T.;
in varying tissues. Despite the apparent biocompatibility of Schaub, R.; Ron, E. Recombinant bone morphogenetic pro-
tein-2 is superior to demineralized bone matrix in repairingthe Helistatt and its capacity as a BMP delivery system,
craniotomies defects in rat. J. Biomed. Mater. Res. 28:1127–a laboratory-produced carrier should be developed that is
1138; 1994.not derived from animal sources. The laboratory-produced 8. Cook, S. D.; Wolfe, M. W.; Salkeld, S. L.; Rueger, D. C.delivery system may be a useful alternative in situations Effect of recombinant human osteogenic protein-1 on healing
where a collagenous delivery system may elicit an immune of segmental defects in non-human primates. J. Bone Joint
Surg. 77A:734–750; 1995.response. A laboratory-produced delivery system could be
9. Sandhu, H. S.; Kanim, L. E.; Kabo, J. M.; et al. Evaluationtailor-made to provide sustained delivery of signaling fac-
of rhBMP-2 with an OPLA carrier in a canine posterolateraltors and to degrade in a time-dependent fashion. (transverse process) spinal fusion model. Spine 20:2669–The goal of our study was to restore osseous structure 2683; 1995.
across CSDs in rabbits’ radii with C and a selected dose 10. Schimandle, J. H.; Boden, S. D.; Hutton, W. C. Experimental
spinal fusion with recombinant human bone morphogeneticof rhBMP-2 and to prove our hypothesis that rhBMP-2
protein-2. Spine 20:1326–1337; 1995.would produce a quantity of bone in the CSD that is equiva-
11. Bostrom, M.; Lane, J.; Tomin, E.; et al. Use of bone morpho-lent to that promoted by the autograft. We were successful genetic protein-2 in the rabbit ulnar nonunion model. Clin.in fulfilling our goal and proving our hypothesis. Further- Orthop. Rel. Res. 327:272–282; 1996.
more, the reproducible and clearly defined animal wound 12. Mayer, M. H.; Hollinger, J. O.; Ron, E.; Wozney, J. Repair of
alveolar clefts in dogs with recombinant bone morphogeneticmodel that is amenable to quantitative morphological as-
protein and poly(a-hydroxy acid) . Plast. Reconstr. Surg.sessments confirms this as a test site to validate the efficacy
98:247–259; 1996.of segmental bone regenerative therapies. This study and 13. Helm, G. A.; Sheehan, J. M.; Sheehan, J. P.; et al. Utilizationprevious studies exploiting the same wound model under- of type I collagen gel, demineralized bone matrix, and bone
score the clinical relevance of a well-defined wound model morphogenetic protein-2 to enhance autologous bone lumbar
that can be used to develop a judicious dosing regimen for spinal fusion. J. Neurosurg. 86:93–100; 1997.
14. Boyne, P. J.; Marx, R. E.; Nevins, M.; et al. A feasibilitythe BMPs.
study evaluation rhBMP-2/absorbable collagen sponge for
maxillary sinus augmentation. Int. J. Periodont. Restor. Dent.
17:11–25; 1997.
CONCLUSION 15. Urist, M. R. Experimental delivery systems for bone morpho-
genetic protein. In: Urist, M. R., Eds. Handbook of Biomate-
rials and Applications, Section 3: Orthopaedic BiomaterialsEfficacy and biocompatibility was validated for the combi- Applications. Boston: Marcel Dekker; 1995:1093–1133.
nation of rhBMP-2 and C. By 8 weeks the combination 16. Harakas, N. K. Demineralized bone matrix-induced os-
was more effective than other treatments in promoting bone teogenesis. Clin. Orthop. Rel. Res. 188:239–251; 1984.
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